Close Menu

NEW YORK (GenomeWeb) – MRM and Biodesix said today that they are partnering to develop mass spectrometry-based assays for lung cancer.

Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI technologies to develop blood-based tests for lung cancer.

MRM's iMALDI method uses upfront enrichment of target proteins followed by MALDI mass spec analysis of those proteins.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.

Jul
17
Sponsored by
GenomeWeb/ABRF

In this webinar, three experts will share advice on how to efficiently manage a mass spectrometry core lab while staying ahead of the technology curve.